Amplyx

Amplyx Pharmaceuticals Inc is a preclinical stage company that re-engineers small molecule drugs and improves their safety and efficacy with two approaches. Our lead program is resulting in the development of novel systemic compounds which remove the immunosuppressive properties of FK506 and are able to employ fungal calcineurin as a new therapeutic target to treat invasive fungal infections.

Focus area
Infectious Diseases & Vaccines
Graduation date
02/28/2017
Commencement date
06/27/2012